The Lancet HIV, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Current Obesity Reports, Год журнала: 2025, Номер 14(1)
Опубликована: Янв. 3, 2025
Язык: Английский
Процитировано
0
Middle East Current Psychiatry, Год журнала: 2025, Номер 32(1)
Опубликована: Янв. 14, 2025
Abstract Background The rising use of antidepressants is critical for managing mental health disorders, but weight gain a concerning side effect, particularly with certain classes like TCAs and SSRIs. This study aims to investigate changes in Omani patients prescribed paroxetine, fluoxetine, mirtazapine, or venlafaxine. Method A cross-sectional conducted from January June 2023 at Sultan Qaboos University Hospital recruited adults disorders on these medications. Weight measurements were taken baseline follow-up, clinically significant defined as ≥ 7% increase. Results total 135 participants analyzed, showing mean 5.54 kg, 60.7% experiencing gain. Mirtazapine paroxetine exhibited the highest average increases (7.51 kg 8.05 respectively) compared fluoxetine (0.69 kg) venlafaxine (4.32 kg). No demographic factors influenced ( p = 0.213). Conclusion highlights among antidepressants, mirtazapine paroxetine. underscores importance monitoring clinical practice necessitates further investigations into individualized treatment strategies manage both weight-related concerns.
Язык: Английский
Процитировано
0
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111312 - 111312
Опубликована: Март 1, 2025
Persistent low mood, anxiety and cognitive deficits are common symptoms of depression highly efficacious treatments that address including dysfunction still required. β-caryophyllene (BCP) is a terpene with anti-inflammatory pro-cognitive properties; however, its efficacy on cognition in remains unclear. This study aimed to investigate acute chronic BCP treatment effects cognitive, depressive- anxiety-like behaviours, inflammation male female Wistar-Kyoto (WKY) rats, rodent model treatment-resistant depression. Rats were administered either (50 mg/kg) or vehicle (control). Open field (OFT), social interaction, sucrose preference, novel object recognition (NOR) elevated plus maze (EPM) tests conducted after (1 h) (2 weeks) treatment. Peripheral plasma inflammatory cytokine levels examined. acutely increased locomotor activity the OFT but did not improve whereas prevented latency first interaction females (not males). preference prevent behaviours EPM. significantly discrimination NOR test WKY rats reduced shows for time improved memory exerted properties depressive-like behaviours. anhedonia sex. These findings demonstrate worthy further investigation.
Язык: Английский
Процитировано
0
Annals of Behavioral Medicine, Год журнала: 2025, Номер 59(1)
Опубликована: Янв. 1, 2025
Depression co-occurs with diabetes at twice the rate, relative to general population without but it is unknown whether depression longitudinally associated control in population. To characterize longitudinal association between depressive symptoms and joint achievement of glycemic, blood pressure (BP), cholesterol (ABC control) among middle-aged older adults (≥50 years) United States. Data nationally representative Health Retirement Study 2006-2017 were pooled across study waves conducted every 2 years. Center for Epidemiological Studies (CES-D8) scale was used assess baseline (≥3 points). Joint ABC 4 years later ascertained using HbA1c (<7.0% [53 mmol/mol] if <65 years, <7.5% [58 ≥65 or <8.0% [64 comorbidities), BP (systolic < 140 diastolic 90 mm Hg), non-HDL (<130 mg/dL). Survey-weighted modified Poisson regressions (risk ratios [RR]) control. The sample consisted 3 332 observations from 531 individuals (mean age: 64.4 [SD: 8.8], 55.4% women). Depressive neither (RR: 0.91 [95% CI, 0.76-1.09]) nor after adjusting covariates. Findings consistent various subgroups defined by age, gender, control, medication use, duration diabetes. Baseline do not compromise future management. Care models should focus on both conditions independently potentially improve overall health.
Язык: Английский
Процитировано
0
Journal of Child and Adolescent Psychopharmacology, Год журнала: 2024, Номер unknown
Опубликована: Дек. 20, 2024
While available for decades, the use of bupropion has increased in recent years. To provide an updated review on bupropion, this article aimed to describe prescription details, potential indication, and treatment duration children, young adults, adults starting treatment.
Язык: Английский
Процитировано
2
The Journal of Clinical Psychiatry, Год журнала: 2024, Номер 85(3)
Опубликована: Авг. 21, 2024
Drugs have actions that may be classified as therapeutic effects and side effects; are do not contribute to benefit.
Язык: Английский
Процитировано
1
Surgery for Obesity and Related Diseases, Год журнала: 2024, Номер unknown
Опубликована: Авг. 1, 2024
Язык: Английский
Процитировано
0
Frontiers in Psychiatry, Год журнала: 2024, Номер 15
Опубликована: Дек. 24, 2024
Background Antidepressant drug treatment may be associated with weight gain, but long-term studies are lacking. Methods We included 3,127 adults (1,701 women) from the REGICOR study, aged 55.6 (SD = 11.6) years on average in 2003–2006, living northeast of Spain. They had data at two time points (baseline and a median 6.3 later) self-reported antidepressant use, body height, baseline smoking, physical activity, diet quality, education, civil status, depressive symptoms assessed Patient Health Questionnaire (PHQ-9) follow-up. defined four trajectories use as follows: never new follow-up, initial discontinued, repeated both points. used multivariable linear models to estimate association these percentage change. In people without obesity (n 2,404), we also estimated incidence Results The 6-year gain was 0.53 kg (1.01% weight), 24.5% participants gained >5% weight. majority (83.6%) did not report any antidepressants, 6.2% initiated during 5.1% discontinued it, reported their analyses, compared users, all were greater gain: +1.78% (0.57, 2.98) for +2.08% (0.97, 3.19) +1.98% (95% CI: 0.75, 3.20) use. non-obese odds ratio becoming obese 2.06 (1.03, 3.96) non-statistically significant other trajectories. Conclusions population-based adult cohort, antidepressants strongly gain. New non-significantly incidence. Given global epidemic widespread management metabolic monitoring should encouraged integrated into depression follow-up guidelines alongside prescriptions.
Язык: Английский
Процитировано
0
The Lancet HIV, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
0